KR950700079A - 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease) - Google Patents

이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)

Info

Publication number
KR950700079A
KR950700079A KR1019940703075A KR19940703075A KR950700079A KR 950700079 A KR950700079 A KR 950700079A KR 1019940703075 A KR1019940703075 A KR 1019940703075A KR 19940703075 A KR19940703075 A KR 19940703075A KR 950700079 A KR950700079 A KR 950700079A
Authority
KR
South Korea
Prior art keywords
interleukin
graft
host disease
versus
subject
Prior art date
Application number
KR1019940703075A
Other languages
English (en)
Inventor
론카롤로 마리아-그라지아
드 왈 말레피트 레네
바켓타 로사
Original Assignee
에릭 에스. 딕커
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에릭 에스. 딕커, 쉐링 코포레이션 filed Critical 에릭 에스. 딕커
Publication of KR950700079A publication Critical patent/KR950700079A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 개체에게 유효량의 인터루킨-10을 투여함을 포함하여, 이식체-대 숙주 질환 또는 이식조직 거부를 억제하는 방법을 제공하는 것에 관한 것이다.

Description

이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 포유동물 세포에서 IL-10를 발현시키는데 사용된 벡터pcD(SRα)의 모식도이다. 제2도는 박테리아에서 IL-10를 발현시키는데 사용된 벡터 TRP-C11의 모식도이다. 제3도는 Xho I 제한부위에 삽입시킨 마우스 IL-10, 바이러스성 IL-10 또는 사람 IL-10의 개방 판독 프레임을 갖는 플라스미드 pGSRG를 나타내며, 이는 또한 최종 작제물의 RBS-ATG-폴리링커 영역의 서열(TAC-RBS로도 부름)을 나타낸다.

Claims (15)

  1. 개체에게 유효량의 인터루킨-10 또는 이의 작용물질을 투여하는 단계를 포함하는, 개체에서 이식체-대-숙주 질환 또는 이식조직 거부를 억제하는 방법.
  2. 제1항에 있어서, 인터루킨-10이 바이러스성 인터루킨-10 및 사람 인터루킨-10으로 구성된 그룹으로부터 선택되는 방법.
  3. 개체에게 유효량의 인터루킨-10을 투여하는 단계를 포함하는, 개체에서 이식체-대-숙주 질환 또는 이식조직 거부를 억제하는 방법.
  4. 제3항에 있어서, 인터루킨-10이 바이러스성 인터루킨-10 및 사람 인터루킨-10으로 구성된 그룹으로부터 선택되는 방법.
  5. 개체에게 유효량의 인터루킨-10을 투여하는 단계를 포함하는, 개체에서 이식조직 거부를 억제하는 방법.
  6. 제5항에 있어서, 인터루킨-10이 바이러스성 인터루킨-10 및 사람 인터루킨-10으로 구성된 그룹으로부터 선택되는 방법.
  7. 제1항에 있어서, 인터루킨-10이 해독후 변이체 또는 뮤테인인 방법.
  8. 개체에게 서열확인번호 3에서 정의한 바와 같은 유효량의 인터루킨-10을 투여하는 단계를 포함하는, 개체에서 이식체-대-숙주 질환 또는 이식조직 거부를 억제하는 방법.
  9. 제8항에 있어서, 인터루킨-10이 바이러스성 인터루킨-10 및 사람 인터루킨-10으로 구성된 그룹으로부터 선택되는 방법.
  10. 이식체-대-숙주 질환 또는 이식조직 거부를 치료하기 위한 인터루킨-10의 용도.
  11. 이식체-대-숙주 질환 또는 이식조직 거부 치료용 약제의 제조를 위한 인터루킨-10의 용도.
  12. 환자에게 유효량의 인터루킨-10을 투여함으로 포함하여, 이식체-대-숙주 질환이 있는 환자를 치료하는 방법.
  13. 이식체-대-숙주 질환 또는 이식조직 거부를 치료하기 위한 인터루킨-10.
  14. 이식체-대-숙주 질환 또는 이식조직 거부를 치료하기 위한, 인터루킨-10을 함유하는 약제학적 조성물의 용도.
  15. 이식체-대-숙주 질환 또는 이식조직을 거부를 치료하는데 유용한 약제학적 조성물을 제조하기 위한 인터루킨-10의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940703075A 1992-03-04 1993-03-02 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease) KR950700079A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84620892A 1992-03-04 1992-03-04
US07/846,208 1992-03-04
PCT/US1993/001665 WO1993017698A1 (en) 1992-03-04 1993-03-02 Use of interleukin-10 to suppress graft-vs.-host disease

Publications (1)

Publication Number Publication Date
KR950700079A true KR950700079A (ko) 1995-01-16

Family

ID=25297256

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940703075A KR950700079A (ko) 1992-03-04 1993-03-02 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)

Country Status (11)

Country Link
EP (1) EP0629130A1 (ko)
JP (1) JPH07504437A (ko)
KR (1) KR950700079A (ko)
CN (1) CN1079166A (ko)
AU (1) AU679908B2 (ko)
CA (1) CA2131524A1 (ko)
IL (1) IL104916A0 (ko)
MX (1) MX9301192A (ko)
NZ (1) NZ249754A (ko)
WO (1) WO1993017698A1 (ko)
ZA (1) ZA931489B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510719A (ja) * 1993-02-01 1996-11-12 ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
JPH10502249A (ja) * 1994-07-05 1998-03-03 スティーノ・リサーチ・グループ・アクティーゼルスカブ 免疫調節剤
WO1996029082A1 (en) * 1995-03-23 1996-09-26 Governors Of Dalhousie College And University A process of prolonging organ allograft survival
US6022536A (en) * 1995-08-09 2000-02-08 Schering Corporation Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
EP0845994A1 (en) * 1995-08-09 1998-06-10 Schering Corporation Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
WO1997026278A1 (en) 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
US6090413A (en) * 1996-03-25 2000-07-18 Lee; Timothy D. Process of prolonging organ allograft survival
WO1998010792A1 (en) * 1996-09-11 1998-03-19 Prendergast Patrick T Immune direction therapy
WO1998020033A2 (en) * 1996-11-06 1998-05-14 Schering Corporation RENATURATION AND PURIFICATION OF VIRAL INTERLEUKIN-10 (vIL-10)
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
WO1999030730A1 (en) * 1997-12-15 1999-06-24 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
EP1061949B1 (en) * 1998-03-03 2009-07-15 University of Southern California Cytokines and mitogens to inhibit graft-versus-host disease
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
JP5008810B2 (ja) 2000-04-11 2012-08-22 ユニバーシティ オブ サザン カリフォルニア 抑制性Ｔ細胞を誘導するためにＴＧＦ−βを用いる移植拒絶反応を防止する方法
CN105106214A (zh) * 2015-08-05 2015-12-02 范国煌 抑制移植物抗宿主病的新型Lck的小分子抑制剂
SG10201606949QA (en) 2016-08-19 2018-03-28 Singapore Health Serv Pte Ltd Immunosuppressive composition for use in treating immunological disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same

Also Published As

Publication number Publication date
ZA931489B (en) 1993-10-28
JPH07504437A (ja) 1995-05-18
WO1993017698A1 (en) 1993-09-16
NZ249754A (en) 1997-06-24
IL104916A0 (en) 1993-07-08
MX9301192A (es) 1994-08-31
CA2131524A1 (en) 1993-09-16
AU679908B2 (en) 1997-07-17
EP0629130A1 (en) 1994-12-21
CN1079166A (zh) 1993-12-08
AU3732893A (en) 1993-10-05

Similar Documents

Publication Publication Date Title
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
DE69721006D1 (de) Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
HUP9902553A2 (hu) Mikrocseppekből álló propofol készítmények
DE69230112T2 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
GR3017535T3 (en) Live vaccines.
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
ES2139578T3 (es) Composiciones y procedimiento para modular la actividad del arn mediante la modificacion de la estructura protectora 5' del arn.
ATE107849T1 (de) Hygienischer zellstoffartikel als einmalartikel und verfahren zu seiner herstellung.
FI913818A0 (fi) Nytt trombolytiskt aemne.
FI801228A (fi) 6-substituerade 11-alkylen-morfantridiner foerfaranden foer deras framstaellning och terapeutiska medel innehaollande dessa
Mutalib et al. Studies on the pathogenesis of staphylococcal osteomyelitis in chickens. II. Role of the respiratory tract as a route of infection
DE69637842D1 (de) Induktion von immunologischer Toleranz
ATE180277T1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
DE69328102D1 (de) Verwendung von gift aus hautflüglern (hymenopteren) zur herstellung eines medikamentes zur behandlung von infektionen durch dna-viren
ATE178651T1 (de) Expression von osteogenem faktor op-1 in mit rekombinantem baculovirus infizierten spodoptera frugiperda-zellen
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
RU95120165A (ru) Лекарственный препарат иммунозамещающего действия на основе клеточной суспензии и способ лечения синдрома приобретенного иммунодефицита (вич-инфекции) с использованием этого препарата
NO20034453L (no) Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter
EP0265548A1 (de) Verfahren zur Herstellung von keimabgetöteten oder in ihrer Virulenz abgeschwächten Substanzen sowie deren Verwendung
KR880701249A (ko) 신규 단백질, 신경류킨
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
DE69837380D1 (de) Biologisches material zur behandlung eines säugetieres durch transfer einesfür einen antikörper kodierendes gen und eine pharmazeutische zusammensetzungdie diese enthält
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
ATE66815T1 (de) Arzneimittel enthaltend einen aus den peyer'schen plaques hergestellten organextrakt zur behandlung bei diabetes mellitus und pankreatitis.
KR890001555A (ko) 요산 배설용 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application